Masimo Files Investor Presentation Highlighting Strategic Initiatives To Deliver Robust Growth And Margin Expansion; Politan Is Making A Bid For Control Without Paying A Premium Or Articulating A Clear Plan Seeking To Replace Masimo Founder, Chairman...
Masimo Files Investor Presentation Highlighting Strategic Initiatives To Deliver Robust Growth And Margin Expansion; Politan Is Making A Bid For Control Without Paying A Premium Or Articulating A Clear Plan Seeking To Replace Masimo Founder, Chairman...
Masimo Files Investor Presentation Highlighting Strategic Initiatives To Deliver Robust Growth And Margin Expansion; Politan Is Making A Bid For Control Without Paying A Premium Or Articulating A Clear Plan Seeking To Replace Masimo Founder, Chairman And CEO Joe Kiani With Politan Nominees
麥斯莫醫療提交投資者演示文稿，重點介紹了旨在提供強勁增長和利潤率擴張的戰略舉措。Politan提出的控制標的的報價未提出明確計劃，也未支付溢價金，並尋求取代麥斯莫醫療的創始人、董事長和CEO Joe Kiani。
Masimo's Strategy Capitalizes on Innovation to Enhance Growth and Create Value for All Stockholders
麥斯莫醫療的策略是利用創新提高增長，爲所有股東創造價值。
Politan is Making a Bid for Control Without Paying a Premium or Articulating a Clear Plan
Politan以不支付溢價或明確計劃來競購控制權。
Politan is Seeking to Replace Masimo Founder, Chairman and CEO Joe Kiani with Inferior Politan Nominees
Politan試圖用次等的Politan提名者取代麥斯莫醫療的創始人、董事長和CEO Joe Kiani。
Politan's Actions are a Threat to Stockholder Value
Politan的行動對股東價值構成威脅。
Masimo Has a Better Plan and Better Nominees
麥斯莫醫療有更好的計劃和提名者。
Strongly Encourages Stockholders to Vote FOR Joe Kiani and Christopher Chavez on the GOLD Proxy Card
強烈建議股東在代理卡上投票支持Joe Kiani和Christopher Chavez。黃金請訪問ProtectMasimosFuture.com以了解更多信息。
Visit ProtectMasimosFuture.com for More Information
訪問 ProtectMasimosFuture.com 了解更多信息
Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI) today filed an investor presentation with the U.S. Securities and Exchange Commission in connection with its Annual Meeting of Stockholders to be held on July 25, 2024. The presentation lays out in detail:
麥斯莫醫療公司（“麥斯莫”或“公司”）（納斯達克證券交易所：MASI）今天在美國證券交易委員會提交投資者演示文稿，以應對於2024年7月25日舉行的其股東年會有關的問題。該演示文稿詳細介紹：
- The Company's robust track record of innovation, led by Masimo Founder, Chairman and CEO Joe Kiani, that supports Masimo's longstanding valuation premium to industry peers;
- Masimo's strategic initiatives for sustained growth and margin expansion that are expected to more than double adjusted EPS to ~$8 by 2029; and
- The Company's belief that Politan's value-destructive agenda to oust Mr. Kiani and take control of Masimo without paying a premium or articulating an exercisable plan poses a significant risk to the value of the Company.
- 由麥斯莫醫療的創始人、董事長和CEO Joe Kiani領導的創新貢獻，支持了麥斯莫醫療長期以來高於行業同行的估值溢價；
- 麥斯莫醫療爲持續增長和利潤率擴張制定的戰略舉措預計將在2029年將調整後的每股收益翻番至約8美元；以及
- 公司相信，Politan的破壞價值議程，即未支付溢價金或提出可行計劃而將Kiani先生趕下臺並控制麥斯莫醫療，對公司價值構成了重大風險。
To safeguard stockholders' investments and ensure continued value creation, the Board strongly recommends that stockholders vote FOR Masimo's highly qualified director nominees, Joe Kiani and Christopher Chavez.
爲保障股東投資並確保持續創造價值，董事會強烈建議股東投票支持麥斯莫醫療的高素質董事任命提名者，即Joe Kiani和Christopher Chavez。
The presentation is available here.
此演示文稿可在此處查看。
譯文內容由第三人軟體翻譯。